Why This Comparison Matters
NeuroStar and EXOMIND sit in the same tms devices category but take different approaches. NeuroStar (Neuronetics) uses Transcranial Magnetic Stimulation (focused figure-8 coil) while EXOMIND (BTL Industries) uses ExoTMS (patented external TMS with proprietary coil design). Both received FDA clearance (2008 and 2024 respectively) and both are actively sold in the US market. The decision between them is rarely about which is objectively better. It's about which fits your specific practice.
Physicians end up comparing these two devices when they're shopping in the $80,000-$150,000 to $100,000-$200,000 price range and want a category leader. Both devices are commonly recommended by sales reps from competing manufacturers, which means physicians often hear inflated claims about one and dismissive claims about the other. This comparison strips out the marketing and looks at pricing, mechanism, evidence, and practice fit side by side.
The Verdict
Choose NeuroStar if your practice prioritizes Neuronetics's ecosystem, brand recognition, or specific clinical advantages. Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset. The pros that matter most: First-mover advantage: largest installed base in the US; 5M+ treatments delivered (largest outcomes registry). The biggest tradeoff to accept: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm).
Choose EXOMIND if BTL Industries's positioning fits better. Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage. The pros that matter most: Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay); BTL's sales and support infrastructure. The biggest tradeoff to accept: Brand new to market (2024 FDA clearance).
For a practice with limited capital that needs maximum flexibility, used pricing tilts the math. NeuroStar used units run $40,000-$80,000; EXOMIND has only a thin used market because it was cleared in 2024. For practices with strong patient flow already, the device that integrates with your existing platforms is usually the right answer even if its standalone specs are slightly weaker. For practices building a category from scratch, brand recognition and patient demand matter more than raw clinical specs. Look at which device patients are already asking for in your market before signing a contract.
EXOMIND vs NeuroStar at a Glance
EXOMIND is BTL Industries' transcranial magnetic stimulation platform, FDA-cleared in 2024 for major depressive disorder on a 6-session protocol. NeuroStar is Neuronetics' figure-8 coil TMS system, FDA-cleared in 2008 and now cleared for MDD, OCD, and anxious depression. Both devices stimulate the left dorsolateral prefrontal cortex. The headline difference is protocol length and clinical track record.
| Factor | NeuroStar | EXOMIND |
|---|
| Manufacturer | Neuronetics (STIM) | BTL Industries |
| FDA cleared | 2008 (depression), 2018 (OCD), 2022 (anxious depression) | 2024 (depression) |
| Coil design | Focused figure-8 coil | ExoTMS proprietary coil |
| Standard protocol | 36 sessions over 6-9 weeks | 6 sessions |
| Session length | 19-37 minutes (3 minutes with theta burst) | Under 30 minutes |
| Device price (new) | $80,000-$150,000 | $100,000-$200,000 [NEEDS VERIFICATION] |
| Per-session reimbursement | $250-$450 (CPT 90867-90869) | Cash-pay common; insurance evolving |
| Treatments delivered | 5M+ globally | Limited public data (2024 launch) |
| Indications | MDD, OCD, anxious depression | MDD (US); anxiety, OCD, binge eating cleared in CA/EU |
Market Leader vs Protocol Disruptor
NeuroStar is the most-installed TMS system in the United States with over 5 million treatments delivered. The installed base means more peer data, more reimbursement precedent, and a larger network of trained operators. When a payer questions medical necessity, NeuroStar's track record carries weight. Neuronetics also offers a per-treatment licensing model that lowers upfront capital outlay for new practices.
EXOMIND's value proposition is the 6-session protocol. A NeuroStar chair running standard protocols treats 2-3 patients in concurrent treatment courses on any given day. EXOMIND's compressed protocol means a single patient course finishes in roughly two weeks instead of nine. Whether that throughput advantage translates to revenue depends entirely on your referral pipeline and on whether your payers reimburse the shorter protocol.
How Much Does EXOMIND Cost?
BTL has not published a list price for EXOMIND. Sales conversations in 2025 and early 2026 suggest a range of $100,000-$200,000 for the device, with bundled pricing offered to practices that already run BTL aesthetic platforms (Emsculpt Neo, Emsella, EXION). [NEEDS VERIFICATION] Patient-facing course pricing varies widely by market. Cash-pay courses for the 6-session protocol have been quoted from roughly $1,800 to $3,500 in early adopter clinics, though pricing is still settling. Insurance coverage in the US is limited as of mid-2026 because most payers built TMS coverage policies around 30-36 session protocols.
If you are evaluating EXOMIND, ask BTL for: a written quote with line items for the device, training, warranty, and consumables; written guidance on which CPT codes BTL recommends billing for the 6-session protocol and which payers have approved coverage in your state; and references from three US practices that have run at least 25 EXOMIND patients to completion.
EXOMIND vs Standard TMS: Is the 6-Session Protocol Real?
The "EXOMIND vs TMS" search pattern reflects confusion in the market. EXOMIND is TMS. It uses transcranial magnetic stimulation in the same regulatory class as NeuroStar, BrainsWay, and MagVenture. The comparison patients are looking for is whether a 6-session course delivers durable remission compared with a 30-36 session course.
The honest answer in mid-2026: the FDA cleared EXOMIND on data BTL submitted, so the agency accepted the short-course evidence for the cleared indication. The longer-term durability data, head-to-head comparisons against 36-session protocols, and real-world remission rates outside the registration trial are still developing. Psychiatrists who want to deploy EXOMIND today should plan for maintenance sessions, follow patients closely for relapse, and document outcomes against an established benchmark. Refer patients to a clinician who can evaluate which protocol fits their depression history and treatment goals.
Is TMS Worth It?
For the patient: TMS has the strongest evidence base in non-pharmacologic depression treatment after ECT. Response rates in clinical trials run 50-60% and remission rates run 30-40% for patients who have failed at least one antidepressant. The treatment is non-invasive, requires no anesthesia, has no cognitive side effects, and lets patients drive themselves home after sessions. The main downsides are time commitment (daily sessions for 6-9 weeks on the standard protocol), scalp discomfort during stimulation, and a small risk of seizure (under 0.1% in published data). Patients considering TMS should consult a board-certified psychiatrist who treats depression and who can evaluate whether TMS is appropriate for their specific history.
For the practice: TMS is one of the few capital purchases in psychiatry that generates meaningful per-patient revenue at insurance rates. A 36-session NeuroStar course at $300-$450 per session reimbursement generates $10,800-$16,200 per patient. A break-even chair running 30 patients a year covers device and maintenance costs and clears margin. The risk factors are payer mix, prior authorization friction, and operator availability. Practices in markets saturated with TMS providers see longer ramp times and tougher reimbursement negotiations.
Session Economics and Verdict
NeuroStar with a 36-session protocol generates $10,800-$16,200 per patient at current Medicare rates. EXOMIND's 6-session protocol, if reimbursed by payers, generates roughly $1,500-$2,700 per patient at comparable per-session rates. Per-patient revenue is dramatically lower for EXOMIND, but revenue-per-chair-hour can be higher if you fill freed-up slots with new patient courses.
The math works for EXOMIND only if your referral pipeline can sustain high patient turnover. A practice doing 3 NeuroStar patients per day generates roughly the same revenue as a practice doing 15-18 EXOMIND patients per day. Most psychiatry practices in mid-sized markets struggle to maintain even 2-3 TMS patients per day on the standard protocol. Bottom line: NeuroStar is the right choice for practices in most US markets in 2026, especially those that need established insurance reimbursement. EXOMIND is worth evaluating for high-volume urban practices with strong referral networks, multi-specialty groups already running BTL platforms, and cash-pay programs that can price the 6-session course attractively. For deeper background, see the NeuroStar device review, the EXOMIND device review, the EXOMIND cost breakdown, and the NeuroStar vs BrainsWay Deep TMS comparison.
Editorial note: this comparison is intended for physician buyers evaluating capital equipment. It is not medical advice. Patients considering TMS for depression, OCD, anxiety, or any indication should consult a board-certified psychiatrist who can evaluate their specific clinical history.
Frequently Asked Questions
Is EXOMIND the same as TMS?
Yes. EXOMIND is a transcranial magnetic stimulation device. It uses pulsed magnetic fields to stimulate the left dorsolateral prefrontal cortex, the same target used by NeuroStar, BrainsWay Deep TMS, and MagVenture. The patient-facing question of 'EXOMIND vs TMS' comes down to protocol length and clinical track record. EXOMIND completes a course in 6 sessions; the established TMS standard is 30-36 sessions.
How much does EXOMIND cost?
BTL has not published a list price. Reported device pricing in sales conversations ranges from $100,000 to $200,000, with bundling available for practices already running BTL platforms. [NEEDS VERIFICATION] Cash-pay course pricing for patients runs roughly $1,800-$3,500 in early adopter clinics, though numbers vary widely by market. Insurance coverage in the US is still developing because most payer policies were built around 30-36 session protocols.
Is TMS worth it for depression?
For appropriately selected patients, the published evidence supports TMS as an effective option after at least one failed antidepressant trial. Clinical trials report 50-60% response rates and 30-40% remission rates. The treatment is non-invasive, requires no anesthesia, and has no cognitive side effects. Downsides include the time commitment for daily sessions, scalp discomfort during stimulation, and a rare seizure risk (under 0.1%). This is a decision to make with a board-certified psychiatrist, not from a comparison page.
Does insurance cover EXOMIND?
As of mid-2026, US insurance coverage for the 6-session EXOMIND protocol is limited. Most commercial payers and Medicare built coverage criteria around longer TMS protocols. Some practices bill the standard TMS CPT codes (90867, 90868, 90869) for EXOMIND sessions with mixed success. Before purchasing, verify coverage policy with your top five payers in writing. Cash-pay programs are how most US EXOMIND practices are operating today.
How is EXOMIND different from NeuroStar's theta burst protocol?
NeuroStar offers an FDA-cleared theta burst (iTBS) protocol that completes a session in roughly 3 minutes per visit, but the patient still attends 36 sessions over the course of treatment. EXOMIND compresses the entire treatment course into 6 visits rather than shortening each visit. The protocols solve different problems: theta burst increases chair throughput per day; EXOMIND reduces patient time-to-completion.
Who should consider EXOMIND over NeuroStar?
EXOMIND is worth a serious look for: multi-specialty practices already running BTL aesthetic platforms that can bundle pricing and training; urban practices with deep referral pipelines that can keep chairs full; and cash-pay programs that can price the 6-session course attractively. NeuroStar is the safer pick for solo psychiatry practices, payer-driven markets, and practices that want the strongest insurance reimbursement track record.
Which is more expensive, NeuroStar or EXOMIND?
NeuroStar runs $80,000-$150,000 new and $40,000-$80,000 used. EXOMIND runs $100,000-$200,000 new, while EXOMIND has only a thin used market (cleared 2024). Per-session pricing is $300-$500 (often insurance reimbursable) for NeuroStar and $400-$600 (cash-pay) for EXOMIND. Annual operating costs (consumables plus maintenance) typically run 5-15% of purchase price for both devices. The right financial comparison includes total cost of ownership over 5 years, not just sticker price.
Which has better clinical evidence, NeuroStar or EXOMIND?
NeuroStar clinical evidence: Strongest in category. 100+ published studies. 5M+ treatment outcomes registry. Multiple FDA clearances backed by large RCTs. EXOMIND clinical evidence: Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing. Evidence quality is not about study count alone. Look at sample sizes, blinded evaluators, independence from manufacturer funding, and outcome durability. Older devices in the same category usually have stronger evidence because they've been studied longer.
Is NeuroStar or EXOMIND more popular in psychiatry practices?
Both NeuroStar and EXOMIND are commonly used in psychiatry, neurology practices. Market share in any given category shifts year to year. Neuronetics and BTL Industries both maintain active sales forces in the US. Ask other physicians in your specialty which platform they're using and why. Peer references in your local market matter more than national market share data.
Are there safety concerns with NeuroStar or EXOMIND?
Both devices are FDA cleared and have established safety profiles. NeuroStar has these documented concerns: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm). EXOMIND has: Brand new to market (2024 FDA clearance). Physicians should monitor FDA MAUDE reports for both devices before purchase. Adverse event trends matter because they signal problems that may not appear in marketing materials. Any device with a sudden spike in MAUDE filings deserves closer scrutiny.
Can I use NeuroStar and EXOMIND in the same practice?
Some practices run both devices, especially when they target different patient segments or treatment areas. The downside is duplicated training, parallel consumable inventories, and potential cannibalization between platforms. The upside is broader marketing claims and the ability to switch patients between platforms if one doesn't deliver expected results. Most practices choose one and commit to mastering it rather than splitting volume.
What's the resale value comparison between NeuroStar and EXOMIND?
Used NeuroStar sells for $40,000-$80,000 on the secondary market. Used EXOMIND barely trades yet because the device was cleared in 2024. Resale values will depend on age, software version, coil condition, and remaining warranty. Devices with strong installed bases hold value better. Devices with active safety signals or declining manufacturer financial health depreciate faster. Resale value should be a factor in any device purchase, especially if practice plans might change in 3-5 years.
NeuroStar vs EXOMIND: which is better for psychiatry practices in 2026?
For psychiatry practices specifically in 2026, the choice between NeuroStar and EXOMIND depends on three factors: existing equipment compatibility (does the new device integrate with what you already run), patient mix and treatment volume (high-volume practices typically benefit from NeuroStar's first-mover advantage: largest installed base in the us while lower-volume practices often prefer EXOMIND's only 6 sessions required (vs 20-36 for neurostar/brainsway)), and total cost of ownership over 5 years including consumables and maintenance. Run the side-by-side TCO analysis with realistic patient volume projections before committing to either platform.
NeuroStar vs EXOMIND: 2026 update on features and clinical evidence?
As of April 2026, both NeuroStar and EXOMIND continue commercial availability from Neuronetics and BTL Industries respectively. Recent updates worth tracking: software releases, new applicator launches, expanded FDA labeling indications, and new peer-reviewed clinical evidence publications. Manufacturer financial stability also matters for long-term support and parts availability. Both manufacturers share business updates periodically that inform the long-term outlook for each device.
How do I choose between NeuroStar and EXOMIND for my practice?
Use a structured decision framework: list 5-7 must-have requirements specific to your patient mix and practice economics, score NeuroStar and EXOMIND against each requirement on a 1-5 scale, weight the requirements by importance, then sum the weighted scores. The platform that scores meaningfully higher (10%+ gap) is the right choice. If the scores are within 10%, secondary factors decide: manufacturer relationship, financing terms, training availability, and resale value. Avoid choosing based on feature breadth alone because most devices in this category have similar feature checkboxes. The differentiation is in workflow fit, treatment results, and total cost over 5 years.
Are there better alternatives to NeuroStar or EXOMIND in the tms devices category?
In the tms devices category, NeuroStar and EXOMIND are often the leading platforms but other alternatives may fit specific practice profiles better. Other category options include brainsway-deep-tms, magventure, nexstim. Run a 4-platform shortlist evaluation rather than a 2-platform binary because hidden alternatives sometimes outperform on the metrics that matter most to your specific practice.